TRDA — Entrada Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1689375 ·
Last close
$6.22
Market Cap
$242.19M
52W High
$16.45
52W Low
$5.55
ADV30
293,646
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 898,000 | — | -44,963,000 | -42,763,000 | 298,877,000 | 99,280,000 | 65,466,000 |
| Mar 2026 | 875,000 | — | -42,303,000 | -39,717,000 | 335,518,000 | 76,444,000 | 64,664,000 |
| Dec 2025 | 1,299,000 | — | -42,208,000 | -39,164,000 | 377,378,000 | 90,394,000 | 71,245,000 |
| Sep 2025 | 1,614,000 | — | -47,051,000 | -44,134,000 | 412,898,000 | 93,286,000 | 72,182,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-134,674,000
Investing CF
$160,164,000
Financing CF
$650,000
CapEx
$-1,474,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.96
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-355,574,000
Inventory
—
Receivables
$816,000
ST Investments
$123,725,000
EBIT TTM
$-176,525,000
Pretax Income TTM
$-164,959,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,686,000
EBITDA
$-170,863,008
Free Cash Flow
$-77,671,624
Enterprise Value
$70,726,488
Total Cash
$223,004,992
Total Debt
$48,544,000
Shares Out
38,936,669
Trailing EPS
$-3.96
Book Value
$7.52
ROE
-54.1%
ROA
-29.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 25,421,000 | -157,898,000 | -143,750,000 | 377,378,000 | 71,245,000 | 306,133,000 | -128,512,000 |
| Dec 2024 | 210,782,000 | 47,011,000 | 65,626,000 | 526,321,000 | 97,643,000 | 428,678,000 | -41,557,000 |
| Dec 2023 | 129,013,000 | -3,162,000 | -6,685,000 | 469,192,000 | 226,832,000 | 242,360,000 | 139,803,000 |
| Dec 2022 | 0 | -97,248,000 | -94,616,000 | 252,056,000 | 39,502,000 | 212,554,000 | -93,786,000 |
TTM Snapshot
Revenues TTM
$83,863,000
NetIncome TTM
$-21,057,000
OpCashFlow TTM
$0
Assets (Latest)
$377,378,000
Forward EPS
$-3.01
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.50 · spot: $6.22 · call volume: 58 · put volume: 20Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PYXS | Pyxis Oncology, Inc. | $241.88M | $2.90 | — |
| CAMP | Camp4 Therapeutics Corp | $241.60M | $3.85 | — |
| LYEL | Lyell Immunopharma, Inc. | $238.68M | $9.74 | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $246.15M | $2.60 | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $246.80M | $6.52 | — |
News headlines (Yahoo Finance, 1h cache)
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
2026-09-10 11:00 · Yahoo
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-02 20:30 · Yahoo
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
2026-06-02 11:00 · Yahoo
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
2026-05-09 06:07 · Yahoo
Entrada’s stock drops as DMD drug’s efficacy falls short
2026-05-08 10:39 · Yahoo
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
2026-05-07 11:00 · Yahoo
Entrada shares dive as Duchenne results disappoint
2026-05-07 11:14 · Yahoo
Entrada Therapeutics Reports First Quarter 2026 Financial Results
2026-05-07 11:10 · Yahoo
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates
2026-05-07 12:50 · Yahoo
Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?
2026-05-05 13:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.